An optimized electrophoresis method for high-resolution imaging of von-Willebrand multimers

Dominik R. Weiss; Christopher Thiel; Erwin F. Strasser; Robert Zimmermann; Reinhold Eckstein

doi:10.1160/TH08-06-0403

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(05): 949-951
DOI: 10.1160/TH08-06-0403

Letters to the Editor

Schattauer GmbH

An optimized electrophoresis method for high-resolution imaging of von-Willebrand multimers

Authors

Dominik R. Weiss

¹Department of Transfusion Medicine and Hemostaseology, University Hospital, Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
Christopher Thiel

¹Department of Transfusion Medicine and Hemostaseology, University Hospital, Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
Erwin F. Strasser

¹Department of Transfusion Medicine and Hemostaseology, University Hospital, Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
Robert Zimmermann

¹Department of Transfusion Medicine and Hemostaseology, University Hospital, Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
Reinhold Eckstein

¹Department of Transfusion Medicine and Hemostaseology, University Hospital, Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

Abstract

Full Text

References

References
1 Tiede A, Priesack J, Werwitzke S. et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Hemost 2008; 04: 569-576.
2 Michiels J, Berneman Z, Gadisseur A. et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von willebrand disease. Clin Appl Thromb Hemost 2006; 12: 397-420.
3 Michiels J, Gadisseur A, Budde U. et al. Characterization, classification, and treatment of von Willebrand diseases: A critical appraisal of the literature and personal experiences. Semin Thromb Hemost 2005; 31: 577-601.
4 Favaloro E, Bonar R, Meiring M. et al. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2BVWD. Thromb Haemost 2007; 98: 346-358.
5 Budde U, Pieconka A, Will K. et al. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32: 514-521.
6 Federici A. Diagnosis of inherited von Willebrand disease: A clinical perspective. Semin Thromb Hemost 2006; 32: 616-620.
7 Sadler J, Budde U, Eikenboom J. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Hemost 2006; 04: 2103-2114.
8 Casonato A, De Marco L, Gallinaro L. et al. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Thromb Haemost 2007; 97: 527-533.
9 Tjernberg P, Vos H, Spaargaren-van Riel C. et al. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. Thromb Haemost 2006; 96: 717-724.
10 Hommais A, Stépanian A, Fressinaud E. et al. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. Thromb Haemost 2006; 95: 776-781.
11 Nurden P, Lanza F, Bonnafous-Faurie C. et al. A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene. Thromb Haemost 2007; 97: 319-321.
12 Szántó T, Schlammadinger A, Salles I. et al. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb Haemost 2007; 98: 251-254.
13 CoxGill J. Diagnosis and treatment of von Willebrand disease. Hematol Oncol Clin North Am 2004; 18: 1277-1299.
14 Franchini M, Targher G, Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol 2007; 86: 699-704.
15 Federici A. Update on the management of von Willebrand disease. Clin Adv Hematol Oncol 2008; 06: 29-31.
16 Bowen DJ, Bowley SJ. Improved visualisation of high-molecular-weight von Willebrand factor multimers. Thromb Haemost 2007; 97: 1051-1052.
17 Blann A. Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 2006; 95: 49-55.
18 Titani K, Kumar S, Takio K. et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-3184.
19 Raines G, Aumann H, Sykes S. et al. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990; 60: 201-212.
20 Smejkal G, Kaul C. Stability of nitroblue tetrazolium-based alkaline phosphatase substrates. J Histochem Cytochem 2001; 49: 1189-1190.
21 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-64.
22 Smejkal G, Shainoff J, Kottke-Marchant K. Rapid high-resolution electrophoresis of multimeric von Willebrand Factor using a thermopiloted gel apparatus. Electrophoresis 2003; 24: 582-587.